In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...

According to him, the industry must address its relationship with the capital markets, address misinformation issues, and push back against the politicization of medical research and development.

Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...

ATTAIN-Maintain found oral orforglipron preserved prior loss after injection-to-oral transition, with only 0.9 kg regain from ...

Toragen is uniquely positioned to navigate this dynamic. Its HPV E5 inhibitor addresses indications that span both sexes: HPV-positive head and neck cancer affects predominantly men, cervical cancer ...

White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

A full clinical hold suspends dosing and enrollment in the Phase III HERO study and open-label extension, superseding the earlier voluntary pause and freezing near-term registrational timelines.

Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...

TRuE-AD4 enrolled adults with 10%–20% BSA moderate atopic dermatitis and prior inadequate response, intolerance, or ...

In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...

Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs ...